Spyre Therapeutics Inc.

NASDAQ: SYRE · Real-Time Price · USD
16.93
0.07 (0.42%)
At close: Aug 15, 2025, 3:59 PM
16.95
0.12%
After-hours: Aug 15, 2025, 07:36 PM EDT

Spyre Therapeutics Balance Sheet Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Cash & Equivalents
81.66M 48.49M 89.42M 71.58M 45.14M 227.55M 188.89M 90.59M 235.36M 35.24M 34.86M 38.99M 37.47M 14.64M 15.14M 24.66M 34.77M 80.23M
Short-Term Investments
444.92M 516.33M 513.66M 342.65M 380.85M 257.09M 150.38M 113.01M n/a 3.23M 20.85M 34.69M 51.08M 52.09M 77.99M 87.76M 93.81M 46.43M
Long-Term Investments
n/a n/a n/a n/a 321K 319K 322K 1.31M 1.32M 1.31M 1.55M 1.53M 1.8M 1.83M 1.84M 1.84M 1.85M n/a
Other Long-Term Assets
n/a 10K 10K 10K 10K 10K 9K 9K 10K 78K 86K 749K 752K 800K 44K 897K 1.55M 2.56M
Receivables
3.5M n/a n/a n/a n/a n/a n/a 163K 1.65M 330K 375K 669K 479K 1.01M 815K n/a n/a 21.5M
Inventory
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Other Current Assets
8.75M 4.95M 5.39M 6.85M 9.74M 2.63M 2.25M 2.19M 2.88M 5.57M 6.17M n/a n/a n/a n/a n/a n/a n/a
Total Current Assets
538.83M 569.77M 608.47M 421.08M 435.74M 487.27M 341.53M 205.95M 239.89M 44.38M 62.26M 82.22M 96.65M 72.6M 98.89M 117.51M 134.37M 151.41M
Property-Plant & Equipment
n/a n/a n/a n/a n/a n/a n/a n/a 2.32M 6.69M 7.25M 7.07M 7.5M 7.95M 9.15M 8.81M 9.22M 9.64M
Goodwill & Intangibles
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Total Long-Term Assets
n/a 10K 10K 10K 331K 329K 331K 1.32M 3.64M 8.08M 8.89M 9.35M 10.06M 10.57M 11.04M 11.55M 12.61M 12.2M
Total Assets
538.83M 569.78M 608.48M 421.09M 436.07M 487.6M 341.86M 207.26M 243.53M 52.45M 71.14M 91.57M 106.71M 83.17M 109.93M 129.06M 146.98M 163.61M
Account Payables
3.71M 3.69M 666K 5.17M 3.23M 3.11M 896K 1.68M 2.85M 2.06M 677K 4.18M 1.96M 2.98M 3.32M 1.86M 2.22M 1.88M
Deferred Revenue
n/a n/a n/a n/a n/a n/a n/a n/a 930K 302K 517K 505K 291K 2.07M 2.36M 4.79M 5.53M 19.23M
Short-Term Debt
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Other Current Liabilities
76.06M 44.74M 52.79M 52.37M 16.23M 37.21M 27.03M 18M 196.07M 6.81M 4.92M 7.72M 9.47M 8.4M 4.99M 9.67M 9.54M 2.1M
Total Current Liabilities
83.06M 70.68M 54.06M 57.54M 22.12M 42.82M 31.98M 44.87M 232.23M 12.64M 14.66M 17.68M 15.86M 16.3M 20.14M 20.43M 20.6M 32.37M
Long-Term Debt
n/a n/a n/a n/a n/a 253.41M 84.56M 387.11M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Other Long-Term Liabilities
n/a 16.49M 36.62M 36.16M 39.56M 39.11M 41.31M 20.69M 216.32M n/a n/a n/a n/a 8K n/a 192K 200K 206K
Total Long-Term Liabilities
n/a 16.49M 36.62M 36.16M 39.56M 292.51M 125.86M 407.8M 218.66M 6.16M 6.18M 6.33M 6.69M 5.21M 5.84M 6.55M 7.35M 7.49M
Total Liabilities
83.06M 87.17M 90.68M 93.7M 61.68M 335.33M 157.84M 452.67M 450.9M 18.8M 20.84M 24.01M 22.55M 21.51M 25.98M 26.98M 27.96M 39.86M
Total Debt
n/a n/a n/a n/a n/a 253.41M 84.56M 387.11M 4.33M 4.43M 4.64M 4.75M 4.79M 4.93M 5.48M 5.16M 5.29M 5.32M
Common Stock
155.83M 13K 13K 12K 12K 10K 10K 7K 6K 6K 6K 6K 6K 5K 5K 5K 5K 5K
Retained Earnings
-1.05B -1.02B -972.43M -916.14M -847.11M -808.27M -764.41M -701.23M -661.13M -444.05M -425.62M -406.8M -388.57M -366.25M -341.81M -321.36M -301.06M -294.23M
Comprehensive Income
454K 682K 180K 1.46M -553K -363K 302K -132K 11K -6K -48K -184K -220K -153K -20K 2K 11K 25K
Shareholders Equity
455.77M 482.61M 517.8M 327.39M 374.38M 152.27M 184.02M -245.4M -207.37M 33.65M 50.3M 67.56M 84.16M 61.66M 83.94M 102.08M 119.02M 123.75M
Total Investments
444.92M 516.33M 513.66M 342.65M 381.17M 257.41M 150.38M 113.01M 1.32M 3.23M 22.4M 36.22M 52.88M 53.92M 79.82M 89.6M 95.66M 46.43M